Navigation Links
Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial
Date:6/16/2008

Pivotal Trial in Medullary Thyroid Cancer Planned to Initiate This Summer

SOUTH SAN FRANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that the company and the U.S. Food and Drug Administration (FDA) have reached agreement on the phase 3 registration trial of XL184, a small molecule anticancer compound targeting MET, RET, and VEGFR2, via the Special Protocol Assessment process. Exelixis has also discussed the trial design with European regulatory agencies. Exelixis is planning to initiate the phase 3 trial of XL184 as a potential treatment for medullary thyroid cancer (MTC) this summer.

The phase 3 trial has been designed in collaboration with internationally renowned experts in the field of thyroid malignancies, including Dr. Steven Sherman from the MD Anderson Cancer Center in Houston, Texas, Drs. Douglas Ball and Barry Nelkin from Johns Hopkins University in Baltimore, Maryland, and Dr. Martin Schlumberger from the Institut Gustave Roussy in Paris, France. This will be a randomized, placebo-controlled, double-blinded study of XL184 as single-agent therapy in 315 patients with unresectable, locally advanced, or metastatic MTC. Patients will be randomized in a 2:1 ratio to receive XL184 or placebo administered as a daily oral dose. The primary endpoint will be duration of progression-free survival. In a planned event-driven analysis, the study size provides 90% power to detect a 75% increase in progression-free survival in patients with documented progressive disease prior to study entry. Secondary endpoints will include overall survival, objective tumor response rate, and changes in serum biomarkers (carcinoembryonic antigen and calcitonin). Additional secondary endpoints will b
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Exelixis Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference
2. Exelixis Receives $150 Million Funding Commitment From Deerfield Management
3. Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield Management
4. Exelixis Announces June 10 Webcast of Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference
5. REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO
6. Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
7. Exelixis Announces May 13 Webcast of Presentation at the Bank of America Health Care Conference
8. Exelixis Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference Call
9. Exelixis Announces April 30 Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
10. Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
11. Option to Develop Exelixis Compound Exercised By Genentech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 Research and ... addition of Jain PharmaBiotech,s new report ... Companies" to their offering. ... report deals with therapeutic drug monitoring, a ... care by monitoring drug levels in the ...
(Date:5/28/2015)... May 27, 2015 Research and ... of Jain PharmaBiotech,s new report "Nanobiotechnology ... offering. An increasing use of ... is anticipated. Nanotechnology will be applied at ... formulations for optimal delivery to diagnostic applications ...
(Date:5/28/2015)... , May 27, 2015 Research ... of Jain PharmaBiotech,s new report "Neuroprotection - ... This report describes the role of ... injuries of the nervous system as well as ... many of the underlying mechanisms of damage to ...
(Date:5/28/2015)... CARLOS, Calif. , May 28, 2015 /PRNewswire/ ... testing, today announced a study published in ... the Panorama single-nucleotide polymorphism (SNP)-based non-invasive prenatal test ... the first trimester. A study ... that complete molar pregnancies occur in about 1 ...
Breaking Biology Technology:Global Therapeutic Drug Monitoring Market 2015-2024 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3
... Corp. (Nasdaq: BSTC ), a biopharmaceutical company developing ... Company will host a conference call and live audio ... 2009 to discuss its third quarter 2009 financial results ... call, please dial 800-860-2442 (domestic) or 412-858-4600 (international). The ...
... Oct. 30 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: BJGP ) ("BMP Sunstone" ... , -- Oppenheimer 20th Annual Healthcare Conference, to be ... Waldorf=Astoria hotel in New York. Management is scheduled, ... and meet with, institutional investors throughout ...
... Sandia researchers have developed a process that can ... Researchers currently use all types of processes to ... small devices," says Sandia materials scientist Jim Martin "people ... to initiate mixing, but these approaches don,t work well." ...
Cached Biology Technology:BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5, 2009 2BMP Sunstone Announces November Investor Conference Participation 2Magnetic mixing creates quite a stir 2Magnetic mixing creates quite a stir 3
(Date:5/19/2015)... DUBLIN , May 19, 2015 /PRNewswire/ ... ) has announced the addition of the  ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A ... provides an in-depth analysis of the current ... introduction of gene-based tests, their working principles ...
(Date:5/11/2015)... May 11, 2015  Synaptics Incorporated (NASDAQ: ... solutions, today announced the appointment of Wajid ... Financial Officer, reporting to Rick Bergman , ... Chief Financial Officer, Kathleen Bayless , who ... Mr. Ali brings extensive financial management expertise ...
(Date:5/8/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leading ... the executive management team will present at the following investor ... Telecom Conference Date: May 18, 2015 Time: 10:40am ... Cowen and Company Technology, Media & ... The New York Palace Hotel, New York, NY ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Synaptics to Present at Upcoming Investor Conferences 2
... Scientists have found the "Rosetta Stone" of supervolcanoes, those ... and massive explosive eruptions that rank among nature,s most ... scale and possibly trigger climatic and environmental effects ... been discovered in the Italian Alps, Sesia Valley by ...
... BEER-SHEVA, September, 21 2009 A researcher who ... has demonstrated that it is possible to test and ... and to anticipate the immune response in Alzheimer,s patients. ... Negev could one day lead to specific Alzheimer,s vaccines ...
... Before it was learned that matter burns by taking ... the release of a mysterious substance, which they named ... chemists conduct experiments and share ideas. Only when it ... phlogiston did it become clear that no such thing ...
Cached Biology News:'Rosetta Stone' of supervolcanoes discovered in Italian Alps 2'Rosetta Stone' of supervolcanoes discovered in Italian Alps 3Ben-Gurion University Alzheimer's researcher demonstrates specific immune response to vaccine 2Echoes of phlogiston in stem cell biology 2